Hagenah J M, König I R, Becker B, Hilker R, Kasten M, Hedrich K, Pramstaller P P, Klein C, Seidel G
Dept. of Neurology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
J Neurol. 2007 Oct;254(10):1407-13. doi: 10.1007/s00415-007-0567-y. Epub 2007 Oct 15.
To further evaluate (1) transcranial sonography (TCS) for (pre)clinical diagnosis of Parkinson's disease (PD) and (2) to examine asymptomatic carriers of Parkin mutations we investigated substantia nigra (SN) hyperechogenicity in PD patients and unaffected subjects with and without Parkin mutations. The area (aSN) of the hyperechogenic SN were calculated bilaterally and study subjects were assigned to high versus low value groups. Eleven of the (affected and unaffected) mutation carriers had previously undergone 18-fluoro-dopa-(FDOPA)-PET scans. Fifty-eight individuals were investigated, including 24 with clinically definite and 34 without symptoms or signs of PD. Of the patients, three had one mutated and six had two mutated Parkin alleles. Of the unaffected subjects, 13 carried a single Parkin mutated allele. After dichotomization, 21 subjects had high and 37 subjects low values of mean aSN. Regarding the clinical status, 13 (62%) of the individuals with a high mean aSN had PD,while 26 (70%) of the study subjects with low values did not show signs of PD (p = 0.0393). Similarly, probands with high mean aSN values more frequently carried Parkin mutations (58%) than probands with low values (27%, p = 0.0234). A negative correlation between FDOPA uptake in the posterior putamen and maximum aSN was found in the group of mutation carriers (r = -0.809, p = 0.0234). In conclusion, hyperechogenicity of the SN is found in both idiopathic and Parkin-associated PD. Further strengthening the notion of a potential relationship between SN hyperechogenicity and Parkin mutational status, a larger aSN was associated with an increasing number of mutated alleles in our study.
为进一步评估(1)经颅超声检查(TCS)在帕金森病(PD)临床前诊断中的应用,以及(2)检测Parkin基因突变的无症状携带者,我们研究了PD患者及有无Parkin基因突变的未患病受试者的黑质(SN)高回声情况。双侧计算高回声SN的面积(aSN),并将研究对象分为高值组和低值组。11名(患病和未患病的)突变携带者之前接受过18-氟多巴(FDOPA)-PET扫描。共对58名个体进行了研究,其中24名有临床确诊的PD,34名无PD症状或体征。在患者中,3名有一个突变的Parkin等位基因,6名有两个突变的Parkin等位基因。在未患病受试者中,13名携带单个突变的Parkin等位基因。二分法划分后,21名受试者aSN平均值高,37名受试者aSN平均值低。就临床状态而言,aSN平均值高的个体中有13名(62%)患有PD,而aSN平均值低的研究对象中有26名(70%)未表现出PD体征(p = 0.0393)。同样,aSN平均值高的先证者比aSN平均值低的先证者更频繁地携带Parkin基因突变(58%比27%,p = 0.0234)。在突变携带者组中,发现壳核后部FDOPA摄取与最大aSN之间呈负相关(r = -0.809,p = 0.0234)。总之,在特发性PD和Parkin相关的PD中均发现SN高回声。在我们的研究中,更大的aSN与突变等位基因数量增加相关,这进一步强化了SN高回声与Parkin突变状态之间潜在关系的概念。